- Home
- HSIC vs ROIV Comparison
HSIC vs ROIV Comparison
Compare HSIC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSIC
- ROIV
- Stock Information
- Founded
- HSIC 1932
- ROIV 2014
- Country
- HSIC United States
- ROIV United Kingdom
- Employees
- HSIC N/A
- ROIV N/A
- Industry
- HSIC Medical Specialities
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- HSIC Health Care
- ROIV Health Care
- Exchange
- HSIC Nasdaq
- ROIV Nasdaq
- Market Cap
- HSIC 8.9B
- ROIV 8.4B
- IPO Year
- HSIC 1995
- ROIV N/A
- Fundamental
- Price
- HSIC $69.14
- ROIV $12.06
- Analyst Decision
- HSIC Buy
- ROIV Strong Buy
- Analyst Count
- HSIC 10
- ROIV 10
- Target Price
- HSIC $77.10
- ROIV $17.39
- AVG Volume (30 Days)
- HSIC 1.9M
- ROIV 5.0M
- Earning Date
- HSIC 11-11-2024
- ROIV 11-11-2024
- Dividend Yield
- HSIC N/A
- ROIV N/A
- EPS Growth
- HSIC N/A
- ROIV N/A
- EPS
- HSIC 2.70
- ROIV 5.65
- Revenue
- HSIC $12,487,000,000.00
- ROIV $158,303,000.00
- Revenue This Year
- HSIC $6.71
- ROIV $45.51
- Revenue Next Year
- HSIC $4.52
- ROIV $37.40
- P/E Ratio
- HSIC $26.03
- ROIV $2.11
- Revenue Growth
- HSIC N/A
- ROIV 101.44
- 52 Week Low
- HSIC $60.01
- ROIV $8.25
- 52 Week High
- HSIC $82.63
- ROIV $13.24
- Technical
- Relative Strength Index (RSI)
- HSIC 49.52
- ROIV 59.17
- Support Level
- HSIC $65.32
- ROIV $12.11
- Resistance Level
- HSIC $70.50
- ROIV $13.06
- Average True Range (ATR)
- HSIC 1.57
- ROIV 0.39
- MACD
- HSIC -0.26
- ROIV -0.00
- Stochastic Oscillator
- HSIC 54.73
- ROIV 47.59
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology & value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology & other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.